Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (MALS verified) , 100µg  

Recombinant Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, His Tag (MALS verified) , 100µg

Recombinant Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Ala 19 - His 240, expressed from human 293 cells (HEK293), His Tag (MALS verified)

Synonym
recombinant cynomolgus protein, CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

More details

CD6-C52H5-100

Availability: within 7 days

312,00 €

Background
Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

Source
Recombinant Cynomolgus / Rhesus macaque B7-2, His Tag (MALS verified) (CD6-C52H5) is expressed from human 293 cells (HEK293). It contains AA Ala 19 - His 240 (Accession # G7NXR4-1). In the region Ala 19 - His 240, the AA sequence of Cynomolgus and Rhesus macaque B7-2 are homologus.
Predicted N-terminus: Ala 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.3 kDa. The protein migrates as 40-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Cynomolgus CD86 by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 2 years in lyophilized state;
-70°C for 1 year under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons"
Naimi, Mohammed, Raji et al
Cell Commun Signal (2022) 20 (1), 44
(2) "Expression of Peripheral Blood DCs CD86, CD80, and Th1/Th2 in Sepsis Patients and Their Value on Survival Prediction"
Du, Hao, Luan
Comput Math Methods Med (2022) 2022, 4672535
(3) "Immmunoinformatics-based design of a multi-epitope vaccine with CTLA-4 extracellular domain to combat Helicobacter pylori"
Ru, Yu, Zhu et al
FASEB J (2022) 36 (4), e22252
Showing 1-3 of 4742 papers.
The following products could also be interesting for you: